Targovax Adjusts Clinical Pipeline After ASCO Disrupts TG Vaccine Program
Executive Summary
Targovax terminates development of TG01 in pancreatic cancer patients after data unveiled at ASCO fundamentally alters development preconditions for its TG vaccine program.
You may also be interested in...
Targovax Pivots Towards Oncolytic Viruses
Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.